文献速递基础与转化研究新药、器械与细胞基因治疗研发

囊性纤维化:机制、诊疗现状与未来方向

Cystic fibrosis.
PubMed 文献 · Lancet · 2021-01-01

囊性纤维化是CFTR突变引起的常染色体隐性单基因病,全球至少10万人受累,表现为慢性肺部感染、胰腺外分泌功能不全和男性不育等。小分子调节剂恢复CFTR功能正改变疾病进程,但随生存期延长和成人患者增多,仍需更多新疗法。

要点

  • CFTR突变致氯和碳酸氢盐转运障碍,黏液水合与清除受损是核心病理。
  • 诊断依据新生儿筛查、多器官临床表现、汗氯升高或CFTR突变。
  • 小分子调节剂恢复CFTR功能,正显著改善部分患者预后。

核心结论

  • CFTR功能恢复的小分子调节剂药物正为许多患者带来疾病转归的改变。
  • 随着生存期改善和成人患者增多,临床研究管线亟需探索更多新方法。

研究设计与样本

  • 本文为综述,汇总CFTR突变、蛋白功能与疾病病理生理的当前认识。
  • 文章评估现有管理策略的优缺点,并展望多学科照护的未来方向。

主要发现

  • 经典囊性纤维化以慢性肺部感染和炎症、胰腺外分泌功能不全及男性不育为特征。
  • 部分患者可合并囊性纤维化相关糖尿病或囊性纤维化肝病等共病。
  • 基因变异导致残余蛋白功能时,疾病表现可不典型,有时仅累及单一器官。

关键数值与推荐

  • 全球至少100 000人受囊性纤维化影响。
  • 诊断可依据新生儿筛查、公认的多器官临床表现、汗氯浓度升高或CFTR突变。

临床怎么用

  • 管理策略包括增强黏液纤毛清除和积极治疗感染,已逐步提高预期寿命。
  • 通过小分子调节剂药物恢复CFTR功能,是当前改变疾病进程的重要治疗方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cystic fibrosis is a monogenic disease considered to affect at least 100 000 people worldwide. Mutations in CFTR, the gene encoding the epithelial ion channel that normally transports chloride and bicarbonate, lead to impaired mucus hydration and clearance. Classical cystic fibrosis is thus characterised by chronic pulmonary infection and inflammation, pancreatic exocrine insufficiency, male infertility, and might include several comorbidities such as cystic fibrosis-related diabetes or cystic fibrosis liver disease. This autosomal recessive disease is diagnosed in many regions following newborn screening, whereas in other regions, diagnosis is based on a group of recognised multiorgan clinical manifestations, raised sweat chloride concentrations, or CFTR mutations. Disease that is less easily diagnosed, and in some cases affecting only one organ, can be seen in the context of gene variants leading to residual protein function. Management strategies, including augmenting mucociliary clearance and aggressively treating infections, have gradually improved life expectancy for people with cystic fibrosis. However, restoration of CFTR function via new small molecule modulator drugs is transforming the disease for many patients. Clinical trial pipelines are actively exploring many other approaches, which will be increasingly needed as survival improves and as the population of adults with cystic fibrosis increases. Here, we present the current understanding of CFTR mutations, protein function, and disease pathophysiology, consider strengths and limitations of current management strategies, and look to the future of multidisciplinary care for those with cystic fibrosis.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Shteinberg M, Haq IJ, Polineni D, et al. Cystic fibrosis. Lancet. 2021. PMID: 34090606. doi:10.1016/S0140-6736(20)32542-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。